BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37191756)

  • 1. PET/MRI for evaluation of patients with pancreatic cancer.
    Duncan ZN; Summerlin D; West JT; Packard AT; Morgan DE; Galgano SJ
    Abdom Radiol (NY); 2023 Dec; 48(12):3601-3609. PubMed ID: 37191756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
    Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
    Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies.
    Gnanasegaran G; Agrawal K; Wan S
    PET Clin; 2022 Jul; 17(3):369-388. PubMed ID: 35717098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
    Lin CY; Lin CL; Kao CH
    Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Interobserver Agreement and Diagnostic Accuracy for IASLC/ITMIG Thymic Epithelial Tumor Staging Among Co-registered FDG-PET/MRI, Whole-body MRI, Integrated FDG-PET/CT, and Conventional Imaging Examination with and without Contrast Media Administrations.
    Ohno Y; Kishida Y; Seki S; Koyama H; Yui M; Aoyagi K; Yoshikawa T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S122-S131. PubMed ID: 29395795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two-way comparison of whole-body 18FDG PET-CT and whole-body contrast-enhanced MRI for distant metastasis staging in patients with malignant tumors: a meta-analysis of 13 prospective studies.
    Li J; Zhou H; Zhang X; Song F; Pang X; Wei Z
    Ann Palliat Med; 2020 Mar; 9(2):247-255. PubMed ID: 32233618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of simultaneous whole-body
    Chan SC; Yeh CH; Yen TC; Ng SH; Chang JT; Lin CY; Yen-Ming T; Fan KH; Huang BS; Hsu CL; Chang KP; Wang HM; Liao CT
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1297-1308. PubMed ID: 29502310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lung cancers: staging and response, CT,
    Owens C; Hindocha S; Lee R; Millard T; Sharma B
    Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Diagnostic Value of F-FDG PET/CT Combined with MRI in Pancreatic Cancer.
    Liu X; Ren Y; Wang J; Yang X; Lu L
    Contrast Media Mol Imaging; 2022; 2022():1479416. PubMed ID: 36017022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET/MR versus PET/CT for locoregional staging of oropharyngeal squamous cell cancer.
    Flygare L; Erdogan ST; Söderkvist K
    Acta Radiol; 2023 May; 64(5):1865-1872. PubMed ID: 36464816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-Body [
    Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
    Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
    Zhang C; Liang Z; Liu W; Zeng X; Mo Y
    BMC Cancer; 2023 Jan; 23(1):37. PubMed ID: 36624425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.